Emcure Pharmaceuticals delivered robust financial performance in Q1FY27, reporting a consolidated revenue of ₹26B, up from ₹21B in the same period last fiscal. The growth was primarily fueled by international operations, which expanded by 34.2% to ₹14,851 million, outpacing domestic sales that grew 10.2% to ₹10,953 million. Consolidated Profit After Tax (PAT) surged to ₹3B compared to ₹2B in the year-ago period, reflecting improved operating leverage and productivity gains. This strong start to FY27 marks the second year of the company's five-year strategic plan, signaling successful execution of its portfolio and integration initiatives.

The Board of Directors approved the unaudited financial results on August 06, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations. The results were reviewed by the Audit Committee and subjected to a limited review by B S R & Co. LLP, the statutory auditors. Alongside financial disclosures, the Board transacted significant governance changes, including the retirement of Chairman Berjis Desai and the appointment of Managing Director & CEO Satish Mehta as the new Chairman effective from the conclusion of the ensuing Annual General Meeting (AGM) on September 21, 2026.

Financial Highlights

The following table summarises Emcure's key consolidated financial metrics for the quarter:

Domestic revenue accounted for 42.4% of total sales, supported by leading brands in CNS, cardiology, and women's health franchises. International revenue contributed 57.6%, with Europe growing 32.8% to ₹5,367 million, Canada rising 24.6% to ₹4,266 million, and Rest of World expanding 44.8% to ₹5,218 million. Gross margin contracted by 340 basis points to 58.4%, attributed to a higher share of international revenue and business mix shifts. However, this was offset by operating efficiency, resulting in EBITDA margin expansion to 20.64%.

Leadership and Corporate Developments

Mr. Berjis Desai, who served as Chairman and Non-executive Director, will cease to hold office at the conclusion of the AGM due to his appointment to the National Commission for Minorities. Consequently, Mr. Satish Mehta has been appointed as Chairman, retaining his role as Managing Director & CEO. Additionally, Mr. Raghu Kumar was appointed as an Additional Independent Director effective August 06, 2026, subject to shareholder approval at the AGM. Mr. Samit Mehta, Whole-time Director, was appointed Chief Operating Officer (COO) with immediate effect.

Strategic Acquisitions and R&D

Emcure completed the acquisition of the remaining 12.05% minority stake in Gennova Biopharmaceuticals Limited on July 21, 2026, making it a wholly owned subsidiary. Mr. Samit Mehta has been appointed CEO of Gennova. Furthermore, Gennova executed a Business Transfer Agreement on July 10, 2026, transferring its mRNA business undertaking for a cash consideration of ₹1,395 million. In Canada, subsidiary Mantra Pharma Inc. acquired 100% of Cutimed Inc. for up to CAD 5.05 million (₹337.54 million) to strengthen its dermatology portfolio.

What the Numbers Show

The divergence between gross margin contraction and EBITDA expansion highlights Emcure's operational discipline. While gross margins fell 340 basis points due to international mix, EBITDA margins rose to 20.64%, indicating that cost controls and productivity gains successfully absorbed the lower-margin international revenue mix. PAT growth significantly outpaced revenue growth, suggesting strong top-line conversion into bottom-line profits. International sales now constitute over half of total revenue, marking a structural shift in the company's geographic footprint.

Regulatory filings confirm compliance with Regulation 33 of the SEBI Listing Regulations. The statutory auditors issued an unqualified conclusion on both standalone and consolidated results. No dividend was declared for the quarter.

Emcure Pharmaceuticals has completed the acquisition of a 12.05% stake in Gennova Biopharmaceuticals Limited for an aggregate consideration of Rs. 2,318.7 Million, making the target entity a wholly-owned subsidiary. The company acquired 663,865 equity shares from individual shareholders, which were duly credited to its demat account on July 21, 2026. This strategic move increases Emcure's shareholding in Gennova from 87.95% to 100%, consolidating control over the biotechnology firm involved in research, development, manufacturing, and marketing of biotechnology-based products.

The acquisition was executed pursuant to Share Transfer Agreements signed on July 13, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction was undertaken at arm's length, with the consideration paid in cash. Gennova reported a turnover of Rs. 4,917.42 Million and a Profit After Tax (PAT) of Rs. 54.25 Million for the financial year ended March 31, 2026.

Financial Overview of Gennova Biopharmaceuticals

Gennova Biopharmaceuticals, incorporated on June 19, 2001, operates within the pharmaceuticals industry. The entity has demonstrated consistent revenue growth over the past three financial years.

Transaction Details

The acquisition was funded entirely through cash consideration. The deal structure involved purchasing the remaining stake held by individual shareholders, thereby eliminating minority interest. No governmental or regulatory approvals were required for the completion of this transaction.

The completion of this acquisition aligns with Emcure's strategy to strengthen its presence in the biotechnology sector. Gennova's operations are entirely based in India, and its integration as a wholly-owned subsidiary is expected to streamline decision-making and operational efficiencies.